Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03202628
What this trial is testing

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 8
Testing effectiveness (Phase 2)Study completedNCT03731832
What this trial is testing

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
GWT-TUD GmbH 66
Early research (Phase 1)Study completedNCT00718601
What this trial is testing

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Who this might be right for
Multiple Myeloma
Geron Corporation 40
Testing effectiveness (Phase 2)Study completedNCT00611351
What this trial is testing

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+4 more
University of Nebraska 5
Early research (Phase 1)Study completedNCT04136756
What this trial is testing

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaIndolent Non-Hodgkin Lymphoma
Nektar Therapeutics 30
Early research (Phase 1)UnknownNCT05549973
What this trial is testing

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 32
Testing effectiveness (Phase 2)Study completedNCT02977494
What this trial is testing

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

Who this might be right for
Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf 22
Early research (Phase 1)Not Yet RecruitingNCT07831122
What this trial is testing

Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Canadian Myeloma Research Group 108
Testing effectiveness (Phase 2)Study completedNCT03848845
What this trial is testing

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 41
Early research (Phase 1)Ended earlyNCT03287908
What this trial is testing

Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Amgen 174
Early research (Phase 1)Looking for participantsNCT06433947
What this trial is testing

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Opna Bio LLC 130
Early research (Phase 1)Looking for participantsNCT07377435
What this trial is testing

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
David Avigan 25
Early research (Phase 1)WithdrawnNCT04998747
What this trial is testing

Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Amgen
Early research (Phase 1)Ended earlyNCT03168438
What this trial is testing

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Who this might be right for
Neoplasms
GlaxoSmithKline 6
Testing effectiveness (Phase 2)Study completedNCT01447914
What this trial is testing

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
National Cancer Institute (NCI) 16
Early research (Phase 1)Study completedNCT02064387
What this trial is testing

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 79
Early research (Phase 1)Looking for participantsNCT06622005
What this trial is testing

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 15
Not applicableNo Longer AvailableNCT05238311
What this trial is testing

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Who this might be right for
Multiple Myeloma
Pfizer
Testing effectiveness (Phase 2)Study completedNCT00066599
What this trial is testing

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Who this might be right for
Kidney CancerLeukemiaLymphoma+6 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT02412878
What this trial is testing

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 478
Next Page